Cases
Antares Pharma, Inc. (ATRS)
Securities Class Action
Overview
Overview
- Date:
- 11/12/2018
- Company Name:
- Atares Pharma, Inc.
- Stock Symbol:
- ATRS
- Status:
- Closed/Complete
NEW YORK, November 12, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Antares Pharma, Inc. (NASDAQ: ATRS).
According to a complaint filed on October 9, 2018, Antares announced its submission of a New Drug Application for Xyosted to the FDA on December 21, 2016. Antares officials spoke optimistically about the drug’s potential while downplaying adverse events involving suicide and high blood pressure that occurred in Xyosted’s clinical trials. On October 12, 2017, Antares revealed that FDA had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for Xyosted.
On this news, Antares’ stock fell nearly 38% to close at $2.32 per share on October 13, 2017. Days earlier, Antares’ Chairman of the Board, Leonard S. Jacob, sold hundreds of thousands of shares of Antares stock, reaping a windfall of nearly $1 million. On October 1, 2018, the company announced that the FDA finally had approved the drug but required a black box warning describing risks of increased blood pressure and suicide.
If you are a long term stockholder of Antares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
According to a complaint filed on October 9, 2018, Antares announced its submission of a New Drug Application for Xyosted to the FDA on December 21, 2016. Antares officials spoke optimistically about the drug’s potential while downplaying adverse events involving suicide and high blood pressure that occurred in Xyosted’s clinical trials. On October 12, 2017, Antares revealed that FDA had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for Xyosted.
On this news, Antares’ stock fell nearly 38% to close at $2.32 per share on October 13, 2017. Days earlier, Antares’ Chairman of the Board, Leonard S. Jacob, sold hundreds of thousands of shares of Antares stock, reaping a windfall of nearly $1 million. On October 1, 2018, the company announced that the FDA finally had approved the drug but required a black box warning describing risks of increased blood pressure and suicide.
If you are a long term stockholder of Antares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.